FINWIRES · TerminalLIVE
FINWIRES

$VTRS

10 stories mentioning VTRSUpdated just now

Every FINWIRES story that references VTRS, newest first.

What are analysts saying about VTRS?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on VTRS?

Wire

Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says

Viatris (VTRS) is facing multiple paths to earnings growth with an improving base business and a late-stage pipeline that includes two potential blockbuster assets, Oppenheimer said in a Wednesday note."We believe the market continues to value Viatris as a declining generics and established-brands company," Oppenheimer said, noting factors such as price declines, declining established brands and generic competition.However, the company's growth in China, new products and value-added medicines should support revenue growth, while an improving mix, share buybacks and about $400 million in expected net savings should drive faster earnings growth, the brokerage noted.Near-term launches of Gwyn Lo and Meloxicam also represent revenue opportunities, potentially bridging Viatris to its 2027 catalysts, Oppenheimer added. These catalysts include Phase 3 data readouts for the company's Selatogrel and Cenerimod therapies in the first half of 2027.Oppenheimer initiated coverage of Viatris with an outperform rating and a $25 price target.Price: $17.09, Change: $-0.09, Percent Change: -0.55%

$VTRS
Research

Oppenheimer Initiates Viatris at Outperform With $25 Price Target

Viatris (VTRS) has an average rating of overweight and mean price target of $19.67, according to analysts polled by FactSet.

$VTRS
Research

Leerink Partners Initiates Viatris at Outperform With $20 Price Target

Viatris (VTRS) has an average rating of overweight and mean price target of $18.71, according to analysts polled by FactSet.

$VTRS
Wire

Viatris' China Policy Concerns Overstated, UBS Says

Viatris' (VTRS) China business remains resilient despite concerns over the country's new volume-control policy, UBS Securities said in a Wednesday note.Concerns seem "overstated" given the China business' increasing profit contribution, above-average margins and shift toward retail and e-commerce channels. Viatris has also raised its outlook for its China business twice this year, the investment firm said.The volume-control policy could impact Viatris' public hospital volumes, but only to a limited extent that should still be offset by retail and self-pay segments. The new policy is also expected to have limited impact on Viatris' larger peers, based on commentary from those companies with significant operations in China, according to the note.About 25% of Viatris' China business comes from public hospitals, while retail and e-commerce channels now account for about 50%, up from roughly 40% in 2021, UBS said. The analysts also noted that key products including Lipitor, Norvasc and Viagra have continued to show growth across hospital and retail channels.UBS has a buy rating and a $23 price target on Viatris.Price: $16.31, Change: $+0.13, Percent Change: +0.83%

$VTRS
Wire

Viatris Obtains US FDA Approval for Contraceptive Patch

Viatris (VTRS) said Wednesday that the Food and Drug Administration has approved its Gwyn Lo patch, a combined hormonal contraceptive patch with low-dose estrogenThe approval was supported by results from a phase 3 study that showed contraceptive efficacy, a well-characterized safety profile and robust patch adhesion performance, Viatris said.Viatris shares were 0.8% higher in Wednesday trading.Price: $18.00, Change: $+0.14, Percent Change: +0.78%

$VTRS
Wire

Goldman Sachs Adjusts Price Target on Viatris to $18 From $17, Maintains Neutral Rating

Viatris (VTRS) has an average rating of overweight and mean price target of $18.14, according to analysts polled by FactSet.Price: $17.37, Change: $-0.23, Percent Change: -1.28%

$VTRS
Wire

Argus Raises Viatris Price Target to $18 From $15

Viatris (VTRS) has an average rating of overweight and mean price target of $18.25, according to analysts polled by FactSet.Price: $16.23, Change: $-0.04, Percent Change: -0.22%

$VTRS
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Viatris Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $18 from $17, 6.6x our 2027 EPS forecast, a discount to peers due to VTRS's slower growth prospects. We adjust our 2026 EPS estimate to $2.48 from $2.45 and maintain our 2027 EPS forecast at $2.72. Viatris reported a strong first quarter for 2026, with total revenues of $3.5B, up 4.7% Y/Y, above expectations, and adjusted EPS of $0.59. The Greater China segment was a standout performer, with revenue accelerating 18% Y/Y, significantly ahead of expectations. This was driven by favorable market fundamentals, strategic investments in selling and marketing, and a more than doubling of sales through e-commerce platforms. While the company raised its growth expectation for China for the full year from low-single digits to mid- to high-single digits, we think policy risks exist in a highly dynamic and unpredictable environment. Next, we see the upcoming U.S. launches of the weekly contraceptive patch XULANE LO and fast-acting meloxicam, to be a key focus to potentially accelerate growth.

$VTRS
Research

Research Alert: Vtrs Q1 Tops Estimates, Driven By Strategic Transformation And Brand Portfolio

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Viatris delivered solid Q1 2026 results with revenues of $3.517B (+8% Y/Y), $150M above consensus, and adjusted EPS of $0.59 (+18% Y/Y), beating consensus by $0.09. Adjusted EBITDA grew 14% Y/Y to $1.049B, demonstrating meaningful operating leverage from the completed strategic review. The brands portfolio showed strong momentum with $2.3B in net sales (+10% Y/Y), driven by exceptional Greater China performance (+22% Y/Y) and continued Emerging Markets strength, while generics stabilized at $1.177B (+5% Y/Y). Management reaffirmed all 2026 guidance ranges, including total revenues of $14.45B-$14.95B and adjusted EPS of $2.33-$2.47, despite incorporating the February Nashik facility fire impact. New product development remained on track with $71M in Q1 revenues toward the $450M-$550M full-year target. In our view, the strategic review has been successful so far to drive operational improvements in Q1, while positioning Viatris for healthy growth.

$VTRS
Sectors

Sector Update: Health Care

Health care stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) retreating by 0.1% and the iShares Biotechnology ETF (IBB) advancing 0.03%.Viatris (VTRS) shares rose more than 1% pre-bell after the company reported higher Q1 financial results and reaffirmed its 2026 guidance.

$IBB$VTRS$XLV

Track with the FINWIRES app suite

FolioX
FolioX
Track VTRS in your portfolio
WheelAI
WheelAI
Analyze VTRS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on VTRS